Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of ticilimumab versus best supportive care after first-line platinum therapy in advanced non-small cell lung cancer
2006-000568-95Phase 2Completed
- Sponsor
- Pfizer
- Start
- Apr 2006
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in non-small cell lung cancer (NSCLC) comparing Ticilimumab with Best supportive care (2 arms). Primary endpoint: Progression-free survival at 3 months. Started Apr 2006; status: completed.
02
Drugs
tremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-000568-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000568-95.